Innovative Eyewear (NASDAQ:LUCY) & Enovis (NYSE:ENOV) Head to Head Contrast

Innovative Eyewear (NASDAQ:LUCY) and Enovis (NYSE:ENOV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Valuation & Earnings

This table compares Innovative Eyewear and Enovis”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innovative Eyewear	$2.66 million	1.63	-$7.59 million	($1.29)	-0.52
Enovis	$2.25 billion	0.66	-$1.18 billion	($19.26)	-1.33

Innovative Eyewear has higher earnings, but lower revenue than Enovis. Enovis is trading at a lower price-to-earnings ratio than Innovative Eyewear, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Innovative Eyewear has a beta of 2.72, meaning that its stock price is 172% more volatile than the S&P 500. Comparatively, Enovis has a beta of 1.34, meaning that its stock price is 34% more volatile than the S&P 500.

Institutional and Insider Ownership

1.0% of Innovative Eyewear shares are owned by institutional investors. Comparatively, 98.5% of Enovis shares are owned by institutional investors. 1.7% of Innovative Eyewear shares are owned by insiders. Comparatively, 2.9% of Enovis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Innovative Eyewear and Enovis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innovative Eyewear	1	1	0	0	1.50
Enovis	1	1	8	0	2.70

Enovis has a consensus target price of $41.29, suggesting a potential upside of 61.59%. Given Enovis’ stronger consensus rating and higher probable upside, analysts clearly believe Enovis is more favorable than Innovative Eyewear.

Profitability

This table compares Innovative Eyewear and Enovis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Innovative Eyewear	-225.26%	-88.90%	-80.34%
Enovis	-47.96%	12.03%	4.91%

Summary

Enovis beats Innovative Eyewear on 9 of the 14 factors compared between the two stocks.

About Innovative Eyewear

Innovative Eyewear, Inc. develops and sells smart eyeglasses and sunglasses. The company's flagship product is Lucyd Lyte glasses that enable the wearer to listen to music, take and make calls, and use voice assistants to perform various smartphone tasks hands-free. It also offers Vyrb, a social media application that enables the user to receive and send posts through Lucyd Lyte smart glasses with voice. In addition, the company launches an application, Lucyd app for iOS/Android users. It sells its products through various e-commerce, and retail store and distribution channels. Innovative Eyewear, Inc. has a license agreement with Lucyd Ltd. The company was incorporated in 2019 and is headquartered in North Miami, Florida. Innovative Eyewear, Inc. is a subsidiary of Lucyd Ltd.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.